MET vs MGRX · P/E 13, rev $38.23B vs rev $456.0K
MetLife Inc (MET) versus Mangoceuticals, Inc. Common Stock (MGRX) — a side-by-side from cached financials, not a winner call.
MetLife Inc (MET) is a insurance - life company listed on US.
Mangoceuticals, Inc. Common Stock (MGRX) is a health information services company listed on US.
Latest reported MET revenue for 2026-06-30 was $38.23B. Net income was $1.92B. MET currently screens at market cap $52.16B and trailing P/E 12.7.
Latest reported MGRX revenue for 2025-12-31 was $456.0K. Net income was -$20.6M. Revenue was down 26.0% from 2024-12-31 to 2025-12-31. MGRX currently screens at market cap $16.3M.
MET currently screens at market cap $52.16B and trailing P/E 12.7. MGRX currently screens at market cap $16.3M.
Not investment advice. Open the MET and MGRX stock pages for the full models.
Not investment advice.